Promentis Pharmaceuticals, Inc.   Report issue

For profit Phase 2
Founded: Milwaukee WI United States (2007)

Organization Overview

First Clinical Trial
2017
NCT03301298
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Promentis Pharmaceuticals | Promentis Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

sxc-2023 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disruptive, Impulse Control, and Conduct Disorders (Phase 2)

Trichotillomania (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 1